Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

NCT04068753 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Cervix Cancer
Progressive Cervix Cancer

Interventions

DRUG: Niraparib
DRUG: dostarlimab

Sponsor

University of Oklahoma

Collaborators

Tesaro, Inc.